The DOI matches its Crossref record; 267 of the 267 references it cites were found in a registry or an index.
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer
Open accessAbstract
Colorectal cancer (CRC) is the third most common cancer and the fourth most common cause of cancer-related death. Most cases of CRC are detected in Western countries, with its incidence increasing year by year. The probability of suffering from colorectal cancer is about 4%–5% and the risk for developing CRC is associated with personal features or habits such as age, chronic disease history and lifestyle. In this context, the gut microbiota has a relevant role, and dysbiosis situations can induce colonic carcinogenesis through a chronic inflammation mechanism. Some of the bacteria responsible for this multiphase process include Fusobacterium spp, Bacteroides fragilis and enteropathogenic Escherichia coli. CRC is caused by mutations that target oncogenes, tumour suppressor genes and genes related to DNA repair mechanisms. Depending on the origin of the mutation, colorectal carcinomas can be classified as sporadic (70%); inherited (5%) and familial (25%). The pathogenic mechanisms leading to this situation can be included in three types, namely chromosomal instability (CIN), microsatellite instability (MSI) and CpG island methylator phenotype (CIMP). Within these types of CRC, common mutations, chromosomal changes and translocations have been reported to affect important pathways (WNT, MAPK/PI3K, TGF-β, TP53), and mutations; in particular, genes such as c-MYC, KRAS, BRAF, PIK3CA, PTEN, SMAD2 and SMAD4 can be used as predictive markers for patient outcome. In addition to gene mutations, alterations in ncRNAs, such as lncRNA or miRNA, can also contribute to different steps of the carcinogenesis process and have a predictive value when used as biomarkers. In consequence, different panels of genes and mRNA are being developed to improve prognosis and treatment selection. The choice of first-line treatment in CRC follows a multimodal approach based on tumour-related characteristics and usually comprises surgical resection followed by chemotherapy combined with monoclonal antibodies or proteins against vascular endothelial growth factor (VEGF) and epidermal growth receptor (EGFR). Besides traditional chemotherapy, alternative therapies (such as agarose tumour macrobeads, anti-inflammatory drugs, probiotics, and gold-based drugs) are currently being studied to increase treatment effectiveness and reduce side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–267 of 267
Cloning of the mRNA of overexpression in colon carcinoma-1
Pibouin-Fragner, L., Villaudy, J., Ferbus, D., Muleris, M., Prosperi, M., Remvikos, Y., & Goubin, G. (2002) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(01)00634-3 · Cited by 99
Prognostic value ofKRASandBRAFmutations in curatively resected colorectal cancer
Kadowaki, S., Kakuta, M., Takahashi, S., Takahashi, A., Arai, Y., Nishimura, Y., Yatsuoka, T., Ooki, A., Yamaguchi, K., Matsuo, K., et al. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i4.1275 · Cited by 98
Kohoutová, D., Šmajs, D., Morávková, P., Cyrany, J., Morávková, M., Forstlova, M., Čihák, M., Rejchrt, S., & Bureš, J. (2014) · BMC Infectious Diseases · doi:10.1186/s12879-014-0733-7 · Cited by 96
APC shuttling to the membrane, nucleus and beyond
Brocardo, M. G., & Henderson, B. R. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.09.002 · Cited by 95
Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages
Li, W., Qiu, T., Zhi, W., Shi, S., Zou, S., Ling, Y., Shan, L., Ying, J., & Lü, N. (2015) · BMC Cancer · doi:10.1186/s12885-015-1345-3 · Cited by 94
Far from the eyes, close to the heart: dysbiosis of gut microbiota and cardiovascular consequences
Serino, M., Blasco-Baque, V., Nicolas, S., & Burcelin, R. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0540-1 · Cited by 93
Li, L., Sun, R., Liang, Y., Pan, X.-M., Li, Z., Bai, P., Zeng, X., Zhang, D., Zhang, L., & Gao, L. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-104 · Cited by 93
Zaharie, F. V., Muresan, M.-S., Petrushev, B., Berce, C., Gafencu, G., Selicean, S. E., Jurj, A. M., Cojocneanu, R., Lisencu, C. I., Pop, L., et al. (2015) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld.2014.1121.244.375 · Cited by 93
Montero, P., Calvo, M. M., Gómez-Guillén, M. C., & Gómez‐Estaca, J. (2016) · LWT · doi:10.1016/j.lwt.2016.02.040 · Cited by 91
Guimarães, R., Barros, L., Carvalho, A. M., & Ferreira, I. C. F. R. (2010) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf101394w · Cited by 90
MicroRNA-320 suppresses colorectal cancer by targeting SOX4, FOXM1, and FOXQ1
Vishnubalaji, R., Hamam, R., Yue, S., Al-Obeed, O. A., Kassem, M. S., Liu, F., Aldahmash, A. M., & Alajez, N. M. (2016) · Oncotarget · doi:10.18632/oncotarget.8937 · Cited by 87
H19 expression in hepatic metastases from a range of human carcinomas
Fellig, Y., Ariel, I., Ohana, P., Schachter, P., Синельников, И. Е., Birman, T., Ayesh, S. K., Schneider, T., de Groot, N., Czerniak, A., et al. (2005) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.023648 · Cited by 86
Metabolites of tobacco smoking and colorectal cancer risk
Cross, A. J., Boca, S. M., Freedman, N. D., Caporaso, N. E., Huang, W., Sinha, R. R., Sampson, J. N., & Moore, S. C. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu071 · Cited by 85
A transcribed pseudogene of MYLK promotes cell proliferation
Han, Y. J., Ma, S. F., Yourek, G., Park, Y., & Garcia, J. G. N. (2011) · The FASEB Journal · doi:10.1096/fj.10-177808 · Cited by 85
Wong, R., & Cunningham, D. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.5024 · Cited by 84
Literature Review and Practical Aspects on the Management of Oxaliplatin-Associated Toxicity
Hoff, P. M., Saad, E. D., Costa, F. P., Coutinho, A. K., Caponero, R., Prolla, G., & Gansl, R. C. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.10.004 · Cited by 84
The microbiota and inflammatory bowel disease: Insights from animal models
Peloquin, J. M., & Nguyen, D. D. (2013) · Anaerobe · doi:10.1016/j.anaerobe.2013.04.006 · Cited by 83
miRNA-99b-5p suppresses liver metastasis of colorectal cancer by down-regulating mTOR
Li, W., Chang, J., Wang, S., Liu, X., Peng, J., Huang, D., Sun, M., Chen, Z., Zhang, W., Guo, W., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4423 · Cited by 82
Hung, R. J., Ulrich, C. M., Goode, E. L., Brhane, Y., Muir, K. R., Chan, A. T., Marchand, L. L., Schildkraut, J. M., Witte, J. S., Eeles, R. A., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv246 · Cited by 82
Mechanisms of cisplatin ototoxicity: theoretical review
Gonçalves, M. S., da Silveira, A. F., Teixeira, A. R., & Hyppolito, M. Â. (2013) · The Journal of Laryngology & Otology · doi:10.1017/s0022215113000947 · Cited by 80
MicroRNA-1246 promotes growth and metastasis of colorectal cancer cells involving CCNG2 reduction
Wang, S., Zeng, Y., Zhou, J., Nie, S., Peng, Q., Gong, J., & Huo, J. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4557 · Cited by 78
Bai, R., Weng, C., Dong, H., Li, S., Chen, G., & Xu, Z. (2015) · International Journal of Cancer · doi:10.1002/ijc.29607 · Cited by 77
Zhang, F., Luo, Y., Shao, Z., Xu, L., Liu, X., Niu, Y., Shi, J., Sun, X., Liu, Y., Ding, Y., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.037 · Cited by 74
Park, Y. R., Lee, S. T., Kim, S., Liu, Y. C., Lee, M. R., Shin, J. H., Seo, S. Y., Kim, S., Kim, I. H., Lee, S. O., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3430 · Cited by 71
Molecular markers for colon diagnosis, prognosis and targeted therapy
Herzig, D. O., & Tsikitis, V. L. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23806 · Cited by 70
MicroRNA-92a Promotes Colorectal Cancer Cell Growth and Migration by Inhibiting KLF4
Lv, H., Zhang, Z., Wang, Y., Li, C., Gong, W., & Wang, X. (2016) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504016x14562725373833 · Cited by 69
Suh, N., Reddy, B. S., DeCastro, A., Paul, S., Lee, H. J., Smolarek, A. K., So, J. Y., Simi, B., Wang, C. X., Janakiram, N. B., et al. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0222 · Cited by 68
Chen, J., Guo, F., Shi, X., Zhang, L., Zhang, A., Jin, H., & He, Y. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-802 · Cited by 67
Qi, P., Xu, M., Ni, S., Shen, X.-H., Wei, P., Huang, D., Tan, C., Sheng, W.-Q., Zhou, X.-Y., & Du, X. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22137 · Cited by 66
The POU5F1P1 pseudogene encodes a putative protein similar to POU5F1 isoform 1
Panagopoulos, I. (1994) · Oncology Reports · doi:10.3892/or_00000105 · Cited by 65
Srivastava, G., Renfro, L. A., Behrens, R. J., Lopatin, M., Chao, C. Y., Soori, G. S., Dakhil, S. R., Mowat, R. B., Kuebler, J. P., Kim, G., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0401 · Cited by 65
Biomarkers of colorectal cancer: Recent advances and future challenges
Coghlin, C., & Murray, G. I. (2014) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400082 · Cited by 62
Day, F. L., Murányi, A., Singh, S., Shanmugam, K., Williams, D., Byrne, D. J., Pham, K., Palmieri, M., Tie, J., Grogan, T. M., et al. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0319-8 · Cited by 60
Wang, F., Zhang, P., Ma, Y., Yang, J., Moyer, M. P., Shi, C., Peng, J., & Qin, H. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.09.033 · Cited by 60
Cancer epidemiology and control in peninsular and island South-East Asia - past, present and future.
Moore, M. A., Manan, A. A., Chow, K. Y., Cornain, S., Devi, C. R. B., Triningsih, F. X. E., Laudico, A. V., Mapua, C. A., Mirasol‐Lumague, M. R., Noorwati, S. , et al. (2010) · PubMed · Cited by 58
Takai, T., Kanaoka, S., Yoshida, K., Hamaya, Y., Ikuma, M., Miura, N., Sugimura, H., Kajimura, M., & Hishida, A. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0937 · Cited by 57
Xu, T., Jing, C., Shi, Y., Miao, R., Peng, L., Kong, S., Ma, Y., & Li, L. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2538 · Cited by 55
MicroRNA-34a targets FMNL2 and E2F5 and suppresses the progression of colorectal cancer
Lu, G.-F., Sun, Y., An, S., Xin, S., Ren, X., Zhang, D., Wu, P., Liao, W., Ding, Y., & Liang, L. (2015) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2015.06.014 · Cited by 55
Atreya, C. E., Sangale, Z., Xu, N., Matli, M. R., Tikishvili, E., Welbourn, W., Stone, S., Shokat, K. M., & Warren, R. S. (2013) · Cancer Medicine · doi:10.1002/cam4.97 · Cited by 54
Wang, L., Jiang, C., Li, D., Ge, X. Q., Shi, Z., Li, C.-Y., Liu, X., Yin, Y., Zhen, L., Liu, L.-Z., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6545 · Cited by 54
Environment and cancer in Brazil: an overview from a public health perspective
Koifman, S., & Koifman, R. J. (2003) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2003.07.005 · Cited by 51
Colorectal cancer genomics: evidence for multiple genotypes which influence survival
Rooney, P. H., Boonsong, A., McKay, J., Marsh, S., Stevenson, D. A. J., Murray, G. I., Curran, S., Haites, N. E., Cassidy, J., & McLeod, H. L. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2095 · Cited by 51
Noguchi, T., Toiyama, Y., Kitajima, T., Imaoka, H., Hiro, J., Saigusa, S., Tanaka, K., Inoue, Y., Mohri, Y., Toden, S., et al. (2016) · Oncology · doi:10.1159/000444493 · Cited by 49
Yadav, D., Ghosh, T. S., & Mande, S. S. (2016) · Gut Pathogens · doi:10.1186/s13099-016-0099-z · Cited by 49
Qiu, Y., Yu, H., Shi, X., Xu, K., Tang, Q., Liang, B., Hu, S.-J., Bao, Y.-J., Xu, J., Cai, J., et al. (2016) · Cell Proliferation · doi:10.1111/cpr.12237 · Cited by 46
New applications of old metal-binding drugs in the treatment of human cancer
Dou, Q. P. (2012) · Frontiers in Bioscience-Scholar · doi:10.2741/s274 · Cited by 45
Sarli, L., Bottarelli, L., Bader, G., Iusco, D. R., Pizzi, S., Costi, R., D’Adda, T., Bertolani, M., Roncoroni, L., & Bordi, C. (2004) · Diseases of the Colon & Rectum · doi:10.1007/s10350-004-0628-6 · Cited by 44
The 15kDa Selenoprotein and Thioredoxin Reductase 1 Promote Colon Cancer by Different Pathways
Tsuji, P. A., Carlson, B. A., Yoo, M., Naranjo‐Suarez, S., Xu, X., He, Y., Asaki, E., Seifried, H. E., Reinhold, W. C., Davis, C. D., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124487 · Cited by 44
Immunohistochemistry for Myc Predicts Survival in Colorectal Cancer
Toon, C. W., Chou, A. S. Y., Clarkson, A., DeSilva, K., Houang, M., Chan, J. C. Y., Sioson, L., Jankova, L., & Gill, A. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087456 · Cited by 44
Inhibition of 19S proteasome-associated deubiquitinases by metal-containing compounds
Liu, N., Huang, H., Dou, Q. P., & Liu, J. (2015) · Oncoscience · doi:10.18632/oncoscience.167 · Cited by 44
Association between polymorphisms in long non-coding RNA PRNCR1 in 8q24 and risk of gastric cancer
Li, L., Fu, J., Bai, P., Liang, Y., Sun, R., Yuan, F., Zhang, L., & Gao, L. (2015) · Tumor Biology · doi:10.1007/s13277-015-3750-2 · Cited by 40
Lenehan, P. F., Boardman, L. A., Riegert‐Johnson, D. L., Petris, G. D., Fry, D. W., Ohrnberger, J., Heyman, E. R., Gérard, B., Almal, A. A., & Worzel, W. P. (2012) · Cancer · doi:10.1002/cncr.27628 · Cited by 39
New applications of old metal-binding drugs in the treatment of human cancer
Sara, M. S. (2011) · Frontiers in Bioscience-Scholar · doi:10.2741/274 · Cited by 38
Zhao, W., Liu, L., Wang, Y., Mao, T., & Li, J. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2846 · Cited by 38
Popat, S., Zhao, D., Chen, Z., Pan, H., Shao, Y., Chandler, I. P., & Houlston, R. S. (2007) · PubMed · Cited by 37
The interplay of long non-coding RNAs and MYC in cancer
Hamilton, M., Young, M. D., Sauer, S., & Martinez, E. (2015) · AIMS Biophysics · doi:10.3934/biophy.2015.4.794 · Cited by 37
Deng, W., Wang, J., Zhang, J., Cai, J., Bai, Z., & Zhang, Z. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-4029-6 · Cited by 33
Health effects of changes in the structure of dietary macronutrients intake in western societies.
Okręglicka, K. (2015) · PubMed · Cited by 32
An analysis of genetic factors related to risk of inflammatory bowel disease and colon cancer
Ryan, B. M., Wolff, R. K., Valeri, N., Khan, M. A., Robinson, D., Paone, A., Bowman, E. D., Lundgreen, A., Caan, B. J., Potter, J. D., et al. (2014) · Cancer Epidemiology · doi:10.1016/j.canep.2014.07.003 · Cited by 32
Sveen, A., Nesbakken, A., Ågesen, T. H., Guren, M. G., Tveit, K. M., Skotheim, R. I., & Lothe, R. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1769 · Cited by 32
The expression and clinical significance of microRNAs in colorectal cancer detecting
Yang, X., Zhong, J., Ji, Y., Li, J., Yu, J., Zhang, J., & Yang, W. (2014) · Tumor Biology · doi:10.1007/s13277-014-2890-0 · Cited by 24
Serological under expression of microRNA-21, microRNA-34a and microRNA-126 in colorectal cancer
de Almeida, A. L. N. R., Bernardes, M. V. A. A., Feitosa, M. R., Peria, F. M., Tirapelli, D. P. D. C., da Rocha, J. J. R., & Féres, O. (2016) · Acta Cirúrgica Brasileira · doi:10.1590/s0102-86502016001300004 · Cited by 24
Smith, B. H., Gazda, L. S., Conn, B. L., Jain, K., Asina, S., Levine, D. M., Parker, T. S., Laramore, M. A., Martis, P. C., Vinerean, H. V., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2258 · Cited by 23
Zhao, L., Zheng, W., WANG, G.-X., Kang, X.-C., Qin, L., Ji, J., & HAO, S. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3414 · Cited by 20
Farazi, P. A. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2014.389 · Cited by 16
McDonald, B. F., Quinn, A. M., Devers, T., Cullen, A., Coulter, I. S., Marison, I. W., & Loughran, S. T. (2015) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12372 · Cited by 8
The potential of proteasome inhibition in the treatment of colon cancer
Konstantinopoulos, P. A., & Papavassiliou, A. G. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.9.1067 · Cited by 8
Cited by
Hibberd, A. A., Lyra, A., Ouwehand, A. C., Rolny, P., Lindegren, H., Cedgård, L., & Wettergren, Y. (2017) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2017-000145 · Cited by 373
PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer
Yaghoubi, N., Soltani, A., Ghazvini, K., Hassanian, S. M., & Hashemy, S. I. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.105 · Cited by 299
Deng, X., Li, Z., Li, G., Li, B., Jin, X., & Lyu, G. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01607 · Cited by 114
Alvandi, E., Wong, W. K. M., Joglekar, M. V., Spring, K. J., & Hardikar, A. A. (2022) · BMC Medicine · doi:10.1186/s12916-022-02529-4 · Cited by 101
IGF2BP2 promotes the progression of colorectal cancer through a YAP‐dependent mechanism
Cui, J., Tian, J., Wang, W., He, T., Li, X., Gu, C., Wang, L., Wu, J., & Shang, A. (2021) · Cancer Science · doi:10.1111/cas.15083 · Cited by 90
Metadata
- Authors
- Mármol, I., Sánchez-de-Diego, C., Pradilla Dieste, A., Cerrada, E., & Rodriguez Yoldi, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-01-19
- Volume
- 18
- Issue
- 1
- Pages
- 197
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2579357550
- Cited by
- 1,525
- References
- 267
- FWCI
- 58.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.